Cargando…

Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells

BACKGROUND: A specific targeting modality for hepatocellular carcinoma (HCC) could ideally encompass a liver cell specific delivery system of a transcriptional unit that is active only in neoplastic cells. Sendai virosomes, derived from Sendai viral envelopes, home to hepatocytes based on the liver...

Descripción completa

Detalles Bibliográficos
Autores principales: Zakaria, Mohammad Khalid, Khan, Imran, Mani, Prashant, Chattopadhyay, Parthaprasad, Sarkar, Debi P, Sinha, Subrata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153911/
https://www.ncbi.nlm.nih.gov/pubmed/25108398
http://dx.doi.org/10.1186/1471-2407-14-582
_version_ 1782333351643840512
author Zakaria, Mohammad Khalid
Khan, Imran
Mani, Prashant
Chattopadhyay, Parthaprasad
Sarkar, Debi P
Sinha, Subrata
author_facet Zakaria, Mohammad Khalid
Khan, Imran
Mani, Prashant
Chattopadhyay, Parthaprasad
Sarkar, Debi P
Sinha, Subrata
author_sort Zakaria, Mohammad Khalid
collection PubMed
description BACKGROUND: A specific targeting modality for hepatocellular carcinoma (HCC) could ideally encompass a liver cell specific delivery system of a transcriptional unit that is active only in neoplastic cells. Sendai virosomes, derived from Sendai viral envelopes, home to hepatocytes based on the liver specific expression of asialoglycoprotein receptors (ASGPRs) which are recognized by the Sendai virosomal fusion (F) proteins. As reported earlier by us and other groups, transcriptional gene silencing (TGS) does not require continuous presence of the effector siRNA/shRNA molecule and is heritable, involving epigenetic modifications, leading to long term transcriptional repression. This could be advantageous over conventional gene therapy approaches, since continuous c-Myc inactivation is required to suppress hepatocarcinoma cells. METHODS: Exploiting such virosomal delivery, the alpha-fetoprotein (AFP) promoter, in combination with various tumour specific enhancers, was used to drive the expression of shRNA directed against ME1a1 binding site of the proto-oncogene c-Myc P2 promoter, in order to induce TGS in neoplastic liver cells. RESULTS: The dual specificity achieved by the Sendai virosomal delivery system and the promoter/enhancer guided expression ensured that the shRNA inducing TGS was active only in liver cells that had undergone malignant transformation. Our results indicate that such a bimodal therapeutic system induced specific activation of apoptosis in hepatocarcinoma cells due to heterochromatization and increased DNA methylation of the CpG islands around the target loci. CONCLUSIONS: The Sendai virosomal delivery system, combined with AFP promoter/enhancer expression machinery, could serve as a generalized mechanism for the expression of genes deleterious to transformed hepatocarcinoma cells. In this system, the epigenetic suppression of c-Myc could have an added advantage for inducing cell death in the targeted cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-582) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4153911
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-41539112014-09-05 Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells Zakaria, Mohammad Khalid Khan, Imran Mani, Prashant Chattopadhyay, Parthaprasad Sarkar, Debi P Sinha, Subrata BMC Cancer Research Article BACKGROUND: A specific targeting modality for hepatocellular carcinoma (HCC) could ideally encompass a liver cell specific delivery system of a transcriptional unit that is active only in neoplastic cells. Sendai virosomes, derived from Sendai viral envelopes, home to hepatocytes based on the liver specific expression of asialoglycoprotein receptors (ASGPRs) which are recognized by the Sendai virosomal fusion (F) proteins. As reported earlier by us and other groups, transcriptional gene silencing (TGS) does not require continuous presence of the effector siRNA/shRNA molecule and is heritable, involving epigenetic modifications, leading to long term transcriptional repression. This could be advantageous over conventional gene therapy approaches, since continuous c-Myc inactivation is required to suppress hepatocarcinoma cells. METHODS: Exploiting such virosomal delivery, the alpha-fetoprotein (AFP) promoter, in combination with various tumour specific enhancers, was used to drive the expression of shRNA directed against ME1a1 binding site of the proto-oncogene c-Myc P2 promoter, in order to induce TGS in neoplastic liver cells. RESULTS: The dual specificity achieved by the Sendai virosomal delivery system and the promoter/enhancer guided expression ensured that the shRNA inducing TGS was active only in liver cells that had undergone malignant transformation. Our results indicate that such a bimodal therapeutic system induced specific activation of apoptosis in hepatocarcinoma cells due to heterochromatization and increased DNA methylation of the CpG islands around the target loci. CONCLUSIONS: The Sendai virosomal delivery system, combined with AFP promoter/enhancer expression machinery, could serve as a generalized mechanism for the expression of genes deleterious to transformed hepatocarcinoma cells. In this system, the epigenetic suppression of c-Myc could have an added advantage for inducing cell death in the targeted cells. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/1471-2407-14-582) contains supplementary material, which is available to authorized users. BioMed Central 2014-08-10 /pmc/articles/PMC4153911/ /pubmed/25108398 http://dx.doi.org/10.1186/1471-2407-14-582 Text en © Zakaria et al.; licensee BioMed Central Ltd. 2014 This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Zakaria, Mohammad Khalid
Khan, Imran
Mani, Prashant
Chattopadhyay, Parthaprasad
Sarkar, Debi P
Sinha, Subrata
Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title_full Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title_fullStr Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title_full_unstemmed Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title_short Combination of hepatocyte specific delivery and transformation dependent expression of shRNA inducing transcriptional gene silencing of c-Myc promoter in hepatocellular carcinoma cells
title_sort combination of hepatocyte specific delivery and transformation dependent expression of shrna inducing transcriptional gene silencing of c-myc promoter in hepatocellular carcinoma cells
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4153911/
https://www.ncbi.nlm.nih.gov/pubmed/25108398
http://dx.doi.org/10.1186/1471-2407-14-582
work_keys_str_mv AT zakariamohammadkhalid combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells
AT khanimran combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells
AT maniprashant combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells
AT chattopadhyayparthaprasad combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells
AT sarkardebip combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells
AT sinhasubrata combinationofhepatocytespecificdeliveryandtransformationdependentexpressionofshrnainducingtranscriptionalgenesilencingofcmycpromoterinhepatocellularcarcinomacells